Clinical trials
Phase 3 Renal Insufficiency, Chronic trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
78 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2007 | 6 |
| 2008 | 1 |
| 2009 | 6 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 8 |
| 2025 | 5 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 38 |
| Terminated | 14 |
| Recruiting | 13 |
| Active, not recruiting | 9 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 9 |
| AstraZeneca | 6 |
| Novartis Pharmaceuticals | 5 |
| Bayer | 4 |
| Eli Lilly and Company | 4 |
| GlaxoSmithKline | 4 |
| Tanabe Pharma Corporation | 4 |
| Astellas Pharma Europe B.V. | 3 |
| Lexicon Pharmaceuticals | 3 |
| Novo Nordisk A/S | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Renal Insufficiency, Chronic | 78 |
| Anemia | 13 |
| Kidney Diseases | 11 |
| Diabetes Mellitus, Type 2 | 10 |
| Kidney Failure, Chronic | 9 |
| Glomerulonephritis, IGA | 7 |
| Hyperparathyroidism, Secondary | 7 |
| Glomerulonephritis | 5 |
| Heart Failure | 4 |
| Hyperphosphatemia | 4 |
Trials
Showing 1 to 25 of 78. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.